REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 36,725 Shares

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 36,725 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $12.86, for a total value of $472,283.50. Following the completion of the sale, the insider owned 213,009 shares of the company’s stock, valued at $2,739,295.74. This trade represents a 14.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steve Pakola also recently made the following trade(s):

• On Monday, June 29th, Steve Pakola sold 19,608 shares of REGENXBIO stock. The stock was sold at an average price of $11.04, for a total value of $216,472.32.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The stock was sold at an average price of $11.02, for a total value of $168,705.18.

REGENXBIO Stock Up 9.3%

NASDAQ:RGNX traded up $1.11 on Wednesday, hitting $13.09. The stock had a trading volume of 4,456,460 shares, compared to its average volume of 2,291,967. REGENXBIO Inc. has a 1-year low of $5.45 and a 1-year high of $16.19. The company has a fifty day moving average price of $8.12 and a two-hundred day moving average price of $9.91. The stock has a market cap of $676.75 million, a price-to-earnings ratio of -2.34 and a beta of 0.90.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.36). The company had revenue of $6.39 million during the quarter, compared to analyst estimates of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. As a group, analysts anticipate that REGENXBIO Inc. will post -3.69 earnings per share for the current year.

Institutional Trading of REGENXBIO

Several hedge funds and other institutional investors have recently modified their holdings of the company. Aquatic Capital Management LLC acquired a new position in shares of REGENXBIO during the 3rd quarter worth about $37,000. Captrust Financial Advisors acquired a new stake in REGENXBIO during the second quarter worth about $85,000. Entropy Technologies LP bought a new position in shares of REGENXBIO in the first quarter valued at approximately $87,000. Prudential Financial Inc. bought a new position in shares of REGENXBIO in the second quarter worth about $87,000. Finally, CANADA LIFE ASSURANCE Co lifted its position in REGENXBIO by 271.8% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 10,839 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 7,924 shares during the period. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of REGENXBIO in a research note on Monday, June 8th. Bank of America decreased their price target on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Robert W. Baird increased their price target on REGENXBIO from $27.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, June 22nd. Morgan Stanley set a $16.00 target price on shares of REGENXBIO in a research report on Friday, May 15th. Finally, Barclays reduced their price target on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, May 15th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.82.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.